Transparency for Large Self-insured Plans
Expanded Access to PBM Data and Audits
Rule Limits and Remaining Questions
CAA, 2026 Highlights
PBMs must provide group health plans and health insurance issuers detailed prescription drug spending data at least twice per year, or quarterly if requested. PBMs must also supply drug spending summary documents that plans can share with participants and beneficiaries upon request.
- The PBM’s summary document; and
- For large plans, information showing the difference between what the plan paid the PBM and what the PBM paid the pharmacy for a covered drug associated with the requesting participant or beneficiary’s claim.
Failure to provide the required information by a PBM or group health plan may result in a civil monetary penalty of $10,000 for each day the information is not reported. Additional penalties may apply if false information is provided. Penalties may be waived for good-faith efforts to comply.
- Prohibiting PBM compensation in Medicare Part D from being tied to the manufacturer’s list price of a drug;
- Requiring the Centers for Medicare & Medicaid Services (CMS) to define and enforce “reasonable and relevant” Medicare Part D contract terms, including reimbursement and dispensing fee information, with enforcement authority to impose monetary penalties; and
- Authorizing CMS to track pharmacy payment trends and pharmacy inclusion in PBM networks, including a designation of “essential retail pharmacies.”
DOL Final Rule
Specifically, PBMs (including PBM-affiliated brokers and consultants) are required to provide initial and ongoing compensation disclosures to fiduciaries of large, ERISA-covered self-insured group health plans (generally those with 100 or more participants). The disclosures will enable these fiduciaries to assess the reasonableness of PBM compensation as part of their ERISA fiduciary duties. The final rule also allows plan fiduciaries to audit the accuracy of PBM disclosures.
- Services: The PBM services, advice, recommendations, or referrals they will deliver under the contract or arrangement;
- Direct compensation: The amount of compensation the PBM reasonably expects to receive directly from the plan or plan sponsor, by service and in total, including the amount allocated to each service in a bundled arrangement;
- Indirect compensation: The amount of compensation the PBM reasonably expects to receive from sources other than the plan or plan sponsor for prescription drug claims during the disclosure period, including manufacturer payments, spread compensation, pharmacy recoupment and price protection agreements;
- Compensation for termination: Any expected compensation related to contract termination, including how prepaid amounts are calculated and refunded;
- Other compensation: Any compensation not already disclosed, including the payer, services involved and a description of the arrangement;
- Formulary placement incentives: Incentives or arrangements with manufacturers that affect drug placement on formularies and their impact on the plan and participant;
- Drug pricing methodology: The net price that will be paid for drugs after rebates and fees, or the methodology used to determine the net price if a monetary amount cannot be determined;
- Statement of fiduciary status: If applicable, a statement that the PBM expects to act as a fiduciary with respect to the plan; and
- Statement of audit rights: A statement explaining the plan’s right to audit the CSP’s disclosures and procedures for requesting an audit.
PBMs must also provide ongoing disclosures on a semiannual basis, or quarterly if the group health plan requests. These disclosures generally include the same categories of compensation as the initial disclosures. According to the DOL, this allows a fiduciary to compare actual compensation with the amounts originally disclosed and monitor the arrangement over time, which helps the fiduciary determine whether the PBM’s compensation remains reasonable.
For each semiannual period, or each quarter if requested by the plan, the PBM must disclose the actual amounts received or reasonably expected to be received for direct compensation, manufacturer payments, spread compensation, pharmacy recoupment, price protection agreements, and any other compensation not covered in these categories. PBMs must also provide a compensation overage explanation if an amount reported in an ongoing disclosure exceeds the amount in the initial disclosure by 5 percent or more (or a lower threshold as agreed to by the parties). The overage explanation must identify the amount of the overage and explain the reason for it.The final rule grants group health plans audit rights to help plan fiduciaries monitor PBMs. Specifically, a group health plan may audit a PBM at least once a year to verify accuracy of its disclosures. The plan has the right to independently choose its auditor, and PBMs may not restrict that choice or limit the timing or location of the audit, or access to information needed for it. PBMs must acknowledge an audit request within 10 business days and generally must provide the necessary information within 60 calendar days.
Employer Takeaways
- Confirm whether the plan is covered and when the first covered plan year begins.
- Review the PBM contract’s renewal date, audit rights and reporting terms.
- Ask the PBM now what it will report, in what format and on what schedule, and raise those points in the next renewal discussion.
- Work out how the new disclosures will fit with the reporting required under the CAA beginning with plan years on or after Aug. 3, 2028.
- Decide now who will review the reports, whether that is the consultant, counsel or an internal team and how to document that review. Then compare those findings against the plan’s cost goals and participants’ needs.
Conclusion
This article is not intended to be exhaustive nor should any discussion or opinions be construed as professional or legal advice. Readers should contact legal counsel for legal advice. © 2026 Zywave, Inc. All rights reserved.